nav-left cat-right
cat-right

Halozyme and Roche Enter Agreement for the Applica...

BASEL, Switzerland and SAN DIEGO, Dec. 5 /PRNewswire/ — Halozyme Therapeutics, Inc. (AMEX:HTI) and Roche today announced they have entered into an agreement to apply Halozyme’s proprietary Enhanze(TM) Technology to Roche’s biological therapeutic compounds. Enhanze Technology is Halozyme’s proprietary drug delivery technology based on its recombinant human hyaluronidase (rHuPH20). rHuPH20 is an analogue...

Multiple Myeloma Research Foundation (MMRF) Awards...

NORWALK, Conn., Dec. 5 /PRNewswire/ — The Multiple Myeloma Research Foundation (MMRF), the largest non-profit foundation dedicated to accelerating a cure for multiple myeloma, today announced that Semafore Pharmaceuticals, Inc. and ProChon Biotech Ltd. are the recipients of the organization’s first LEAD (Leveraging Existing Multiple Myeloma Targets to Accelerate Drug Discovery and Development) research and...

Wyeth acquires global license for InpharmaticaR...

Inpharmatica Ltd today announces that Wyeth Pharmaceuticals, a division of Wyeth has licensed Admensa Interactive, Inpharmatica’s platform of predictive drug absorption, distribution, metabolism and excretion models and compound prioritization tools. Wyeth will use Admensa Interactive to support compound selection and optimization in its drug discovery projects. This new license, agreed after an extensive evaluation,...

EpiCept Announces IND Filing of Novel Compound wit...

NGLEWOOD CLIFFS, New Jersey, October 2 /PRNewswire/ — – EPC2407 Latest Clinical Candidate from Company’s Apoptosis ScreeningTechnology EpiCept Corporation (Nasdaq: EPCT; OMX Stockholm) today announced that ithas submitted an investigational new drug (IND) application to the U.S. Foodand Drug Administration (FDA) to begin Phase I clinical studies of EPC2407 incancer patients. EPC2407 is the Company’s...

Evotec Discontinues EVT 301 Development Programme

HAMBURG, Germany and OXFORD, England, September 13 /PRNewswire-FirstCall/ — Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today reported that during the one month safety and tolerability study with EVT 301 in young and elderly volunteers, several cases of asymptomatic elevated liver function tests in the elderly group have been observed. All cases reversed spontaneously. No cases of elevated liver function tests...

Virtual screening services collaboration between Q...

Quantum Pharma, a drug discovery and computational chemistry software and contract services provider, Moscow, Russia, and TimTec, a provider of synthetic organic and natural compounds for bioscreening, Delaware, US, singed up a collaboration agreement. Quantum computational chemistry software with unique capabilities is available now through TimTec. In the future companies will co-develop products for drug-discovery utilizing...
Page 10 of 15« First...89101112...Last »